ReviewChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Pediatric medulloblastoma.
Review in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma is the most common malignant brain tumor of childhood and remains a leading cause of pediatric cancer-related mortality. Once treated as a single clinicopathologic entity, medulloblastoma is now recognized as a biologically heterogeneous family of diseases defined by four principal molecular subgroups (WNT, SHH, Group 3, and Group 4) and further refined by methylation-defined subtypes. These biologic categories differ in genetics, developmental origin, age distribution, dissemination patterns, and prognosis, and they increasingly guide risk stratification and treatment selection. Over recent decades, advances in neurosurgery, radiotherapy, and multiagent chemotherapy have improved survival, but at the cost of substantial neurocognitive, endocrine, and psychosocial late effects. Contemporary trials are aimed at reducing therapy intensity for biologically favorable disease while intensifying or innovating approaches for very high-risk subgroups. In parallel, emerging biomarkers such as cerebrospinal fluid (CSF) cell-free DNA (cfDNA) assays are under evaluation for measurable residual disease monitoring and response-adapted therapy. This review summarizes key concepts in medulloblastoma biology, outlines the evolution of pediatric therapy and trials, describes modern treatment strategies across age and risk groups, and highlights future directions in molecular risk stratification and biomarker-driven clinical trials.
Indexed as
Identifiers
42365163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.